Immunotherapy Advances for Epithelial Ovarian Cancer

Cancers

ErinG. Hartnett¹  RonaldJ. Buckanovich¹  Mackenzy Radolec¹  AndaM. Vlad¹  RobertP. Edwards¹  Julia Knight² 

[1] Department of Obstetrics and Gynecology and Reproductive Sciences, School of Medicine, University of Pittsburgh, Magee- Womens Research Institute and Foundation and Magee-Womens Hospital of UPMC, Pittsburgh, PA 15213, USA;School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA;

关键词: epithelial ovarian cancer;    immune therapy;    cancer vaccines;    immune checkpoint inhibitors;    CAR T cells;    oncolytic viruses;   

DOI  :  10.3390/cancers12123733

来源: DOAJ

【 摘 要 】

New treatment modalities are needed in order to improve the prognosis of women diagnosed with epithelial ovarian cancer (EOC), the most aggressive gynecologic cancer type. Most ovarian tumors are infiltrated by immune effector cells, providing the rationale for targeted approaches that boost the existing or trigger new anti-tumor immune mechanisms. The field of immuno-oncology has experienced remarkable progress in recent years, although the results seen with single agent immunotherapies in several categories of solid tumors have yet to extend to ovarian cancer. The challenge remains to determine what treatment combinations are most suitable for this disease and which patients are likely to benefit and to identify how immunotherapy should be incorporated into EOC standard of care. We review here some of the most promising immune therapies for EOC and focus on those currently tested in clinical trials.

【 授权许可】

Unknown